FILE PHOTO: A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid
(Reuters) – The U.S. Food and Drug Administration on Friday approved AbbVie Inc’s new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.
The drug, Rinvoq, also called upadacitinib, was approved to treat rheumatoid arthritis, according to a notice from the FDA.(bit.ly/2KFUa5H)
Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel
Our Standards:The Thomson Reuters Trust Principles.
source: reuters.com